Prothena Corp (PRTA) Expected to Announce Quarterly Sales of $270,000.00

Brokerages expect that Prothena Corp (NASDAQ:PRTA) will report $270,000.00 in sales for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Prothena’s earnings, with the highest sales estimate coming in at $390,000.00 and the lowest estimate coming in at $200,000.00. Prothena reported sales of $26.81 million in the same quarter last year, which indicates a negative year-over-year growth rate of 99%. The business is scheduled to announce its next earnings results on Tuesday, August 14th.

According to Zacks, analysts expect that Prothena will report full year sales of $1.07 million for the current fiscal year, with estimates ranging from $900,000.00 to $1.40 million. For the next financial year, analysts expect that the firm will report sales of $66.16 million per share, with estimates ranging from $25.95 million to $121.63 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Prothena.

Prothena (NASDAQ:PRTA) last announced its earnings results on Tuesday, May 8th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.03). The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $31.45 million. Prothena had a negative net margin of 606.09% and a negative return on equity of 38.08%.

Several analysts recently issued reports on PRTA shares. Cantor Fitzgerald restated a “buy” rating and set a $65.00 target price on shares of Prothena in a research report on Sunday, February 4th. ValuEngine lowered shares of Prothena from a “sell” rating to a “strong sell” rating in a research report on Wednesday, February 7th. BidaskClub lowered shares of Prothena from a “sell” rating to a “strong sell” rating in a research report on Thursday, February 8th. Oppenheimer set a $70.00 target price on shares of Prothena and gave the company a “buy” rating in a research report on Thursday, February 15th. Finally, Zacks Investment Research upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research report on Monday, February 19th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. Prothena currently has a consensus rating of “Hold” and a consensus price target of $51.83.

Shares of Prothena opened at $15.60 on Friday, according to Marketbeat.com. The company has a market cap of $656.27 million, a P/E ratio of -3.83 and a beta of 2.77. Prothena has a 12-month low of $16.31 and a 12-month high of $16.81.

Several institutional investors and hedge funds have recently bought and sold shares of PRTA. LPL Financial LLC bought a new position in shares of Prothena in the first quarter worth approximately $210,000. HBK Investments L P bought a new position in shares of Prothena in the fourth quarter worth approximately $213,000. Aperio Group LLC bought a new position in shares of Prothena in the first quarter worth approximately $222,000. Oppenheimer & Co. Inc. bought a new position in shares of Prothena in the first quarter worth approximately $284,000. Finally, Jefferies Group LLC bought a new position in shares of Prothena in the fourth quarter worth approximately $292,000.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.

Get a free copy of the Zacks research report on Prothena (PRTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit